Emil Lou, MD, PhD, FACP

Emil Lou, MD, PhD, FACP

Durham NC —Bryan R. The problem is, cancer cells find their way to other parts of the brain and are very hard to kill. and Ph.D. Using K12 and K08 funding I developed a rabbit model to study the fetal and placental effects of oral pathogens. He performed his residency training in Internal Medicine at Duke University Medical Center and then subsequently completed his Medical Oncology and Hematology fellowship at the Memorial Sloan-Kettering Cancer Center in 2010. Cullen was awarded this honor in recognition of his many important contributions to the field of virology while at Duke, including the discovery of the mechanisms of action of the essential HIV-1 proteins Tat and Rev and his demonstration of the key role played by small non-coding RNAs in regulating herpes virus latency. Last October, for instance, the FDA approved Imlygic, an engineered version of the herpes virus, for the treatment of the deadly skin cancer melanoma.

Lou, a diplomate of the American Board of Internal Medicine, is board certified in Medical Oncology and Internal Medicine. My goal is to integrate these fellow and faculty training programs in a such a way to capitalize on the enormous research infrastructure present as well as synergize campus wide efforts in women’s health research to improve health outcomes for the women and children we serve. He joined the faculty in the Division of Hematology, Oncology and Transplantation in 2011 and is a member of the Masonic Cancer Center, University of Minnesota. Publications Link to Dr. The focal point of the segment, however, was the story of Nancy Justice, a wife and mother in her late 50s. Serum biomarkers associated with clinical outcomes fail to predict brain metastases in patients with stage IV non-small cell lung cancers. Moreover, I maintain close, active, and collaborative relationships with reproductive health researchers at FHI360, Gynuity Health Projects in New York, California Family Health Council, and elsewhere.

*Co-first authors.E Lou. Intercellular conduits in tumors: the new social network. The researchers said, however, that she lived nine months longer than she would have otherwise. January 1 2016.E Lou and PW Sperduto. Walter L. Invited Perspectives article, Annals of Translational Medicine, 2016; 4(2):36. doi: 10.3978/j.issn.2305-5839.2015.12.42Y Ji, RI Vogel, E Lou.

Kroll also noted that only a small fraction of glioblastoma patients will likely be accepted into research trials looking into this therapy. Neuro-Oncology Practice, advance access online November 12, 2015.KP Peters*, E Lou*, A Desjardins, DA Reardon, ES Lipp, E Miller, JE Herndon, F McSherry, HS Friedman, JJ Vredenburgh. Recent work has focused on using these methods to help with guidelines development (including a current update to the American Cancer Society’s breast cancer screening recommendations), research prioritization, and research design. The Oncologist, published online May 29, 2015. (*co-first authors)S Gholami, A Marano, NG Chen, RJ Aguilar, A Frentzen, C-H Chen, E Lou, S Fujisawa, C Eveno, L Belin, P Zanzonico, A Szalay, Y Fong. Until now, treatment options for patients 65 and older have been limited, as few studies have looked at whether that age group responds to chemotherapy. Breast Cancer Research and Treatment.

Nov 13 2014 (Epub ahead of print).J Ady, S Desir, V Thayanithy, RI Vogel, AL Moreira, RJ Downey, Y Fong, K Manova-Todorova, MAS Moore, E Lou. Intercellular communication in malignant pleural mesothelioma: Properties of Tunneling Nanotubes. Frontiers in Physiology, published online September 26, 2014.V Thayanithy, E Dickson, C Steer, S Subramanian, E Lou. But there is still a long road to travel, with many unanswered questions about the risks and the types of patients who will benefit. Translational Research, pii: S1931-5244(14)00198-4. May 2014. doi: 10.1016/j.trsl.2014.05.011S Gholami, C-H Chen, S Gao, E Lou, S Fujisawa, J Carson, JE Nnoli, T-C Chou, J Bromberg, Y Fong.

Emil Lou, MD, PhD, FACP
Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Therapy, June 13, 2014. doi: 10.1038/cgt.2014.28. [Epub ahead of print]V Thayanithy, V Babatunde, E Dickson, P Wong, S Oh, X Ke, A Barlas, S Fujisawa, Y Romin, A Moreira, R Downey, C Steer, S Subramanian, K Manova-Todorova, M Moore, E Lou. Tumor exosomes induce tunneling nanotubes in lipid raft-enriched regions of human mesothelioma cells. Experimental Cell Research, 323(1):178-88. April 15 2014 (Epub 2014 Jan 24).

doi: 10.1016/j.yexcr.2014.01.014.E Lou, M Johnson, C Sima, R Gonzalez-Espinoza, M Fleisher, MG Kris, CG Azzoli. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer. Cancer Biomarkers, 14(4):207-14. January 2014. doi: 10.3233/CBM-140399.N Aburjania, AM Truskinovsky, MJ Overman, E Lou. Ampulla of Vater Adenocarcinoma in a BRCA2 Germline Mutation Carrier. Journal of Gastrointestinal Cancer, published online February 17, 2013.

45(1): pp 87-90, March 2014.E Lou, S Subramanian, CJ Steer. Pancreatic Cancer: Modulation of KRAS, MicroRNAs and Intercellular Communication in the Setting of Tumor Heterogeneity. Pancreas 42(8), 1218-26, November 2013.S Gholami, C-H Chen, E Lou, LJ Belin, S Fujisawa, VA Longo, NG Chen, M Gönen. PB Zanzonico, AA Szalay, Y Fong. Vaccinia Virus GLV-1h153 in combination with 131-I-iodine shows increased efficiency in treating Triple-Negative Breast Cancer. FASEB Journal, November 1 2013 (Epub ahead of print).E Lou, KP Peters, AL Sumrall, A Desjardins, DA Reardon, ES Lipp, JE Herndon II, A Coan, L Bailey, S Turner, HS Friedman, JJ Vredenburgh. Phase II trial of upfront Bevacizumab and Temozolomide for unresectable or multifocal glioblastoma.

Cancer Medicine 2(2): 185-95, April 2013; Epub January 24, 2013.D Reardon, JE Herndon II, KB Peters, A Desjardins, A Coan, E Lou, AL Sumrall, S Turner, ES Lipp, S Sathomsumetee, JN Rich, JH Sampson, AH Friedman, ST Boulton, DD Bigner, HS Friedman, JJ Vredenburgh. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer, October 4 2012. doi: 10.1038/bjc.2012.415.E Lou, A Sumrall, S Turner, K Peters, A Desjardins, JJ Vredenburgh, R McLendon, JE Herndon II, F McSherry, J Norfleet, HS Friedman, DA Reardon. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. Journal of Neurooncology, 2012 August;109(1):63-70. Epub 2012 Apr 26.E Lou, S Fujisawa, A Barlas, Y Romin, K Manova-Todorova, M.A.S.

Moore, S Subramanian. Tunneling Nanotubes: A new paradigm for studying intercellular communication and therapeutics in cancer. Communicative & Integrative Biology 5(4): 399-403, July 2012. doi: 10.4161/cib.20569.E Lou, S Fujisawa, A Morozov, A Barlas, Y Romin, Y Dogan, AL Moreira, K Manova-Todorova, MAS Moore. Tunneling Nanotubes Provide a Unique Conduit for Intercellular Transfer of Cellular Contents in Human Malignant Pleural Mesothelioma. PLoS ONE 7(3):e33093. Epub 2012 Mar 9.A Morozov, R Downey, J Healey, A Moreira, E Lou, A Franceschino, Y Dogan, R Leung, M Edgar, M LaQuaglia, RG Maki, MAS Moore.

Benign Mesenchymal Stem Cells in Human Sarcomas. Clinical Cancer Research 16(23): 5630-40, December 1 2010.N Girard, E Lou, CG Azzoli, R Reddy, M Robson, M Harlan, I Orlow, Y Yatabe, M Ladanyi, A Viale, MG Kris, G Riely, V Miller, RJ Klein, K Matsuo, W Pao. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clinical Cancer Research, 16(2):755-63 (Epub 2010 Jan 12), January 15, 2010.C Griffith, S Noonan, E Lou, EJ Shillitoe. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16. Cancer Gene Therapy, 14: 985-993, December 2007.E Lou, J Marshall, M Aklilu, D Cole, D Chang,, and M Morse. A Phase II Study of Active Immunotherapy with PANVACTM or Autologous, Cultured Dendritic Cells Infected with PANVACTM after Complete Resection of Hepatic Metastases of Colorectal Carcinoma.

Invited review, Clinical Colorectal Cancer, 5(5): 368-71, January 2006.

You may also like